Biomarkers in Radiation Oncology: Past, Present and Future - AM2019
Biomarkers have revolutionized how we treat certain cancers (e.g. breast cancer, medulloblastoma, H&N cancer, etc.), sometimes even providing more prognostic information than traditional measures such as age, stage, grade and performance status. However, clinician uptake of novel biomarkers is poor, largely because of incomplete understanding of the science behind the development of biomarkers and the overwhelming amount of new information each year. This course will attempt to put biomarker development in context, emphasizing the common biomarkers and their development, the use of novel biomarkers today, and the state of the field in the future. Participants will be able to better implement biomarkers in their everyday practice after this session, and understand the rationale behind correlative studies in cooperative group trials, so as to better inform their patients.
The meeting is designed to meet the interests of radiation oncologists, medical oncologists, surgeons, pathologists, radiation biologists, and residents.
- Identify current biomarkers in routine use and describe their clinical significance.
- Explain the difference between predictive and prognostic biomarkers and be able to identify the corresponding therapies.
- Discuss the importance of correlative studies regarding biomarker development with their patients when consenting them to cooperative group trials.
The following persons served as faculty for this activity:
Anthony Apicelli, MD, PhD is employed at VA St. Louis Health Care System and has no financial relationships to disclose.
Adam Dicker, MD, PhD, FASTRO is employed at Thomas Jefferson University and receives compensation/remuneration/funding from the Janssen, Roche and Wilson Socini.
Felix Feng, MD is employed at University of California San Francisco and receives compensation/remuneration/funding from Janssen, Nutcracker Therapeutics, Zenith, and holds a leadership position in PFS Genomics.
Quynh Le, MD, FASTRO is employed at Stanford Cancer Institute and receives compensation/remuneration/funding from Merck.
Additionally, the Education and CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.